Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

1.

HER-3 expression in HER-2-amplified breast carcinoma.

Czopek J, Pawlęga J, Fijorek K, Püsküllüoğlu M, Różanowski P, Okoń K.

Contemp Oncol (Pozn). 2013;17(5):446-9. doi: 10.5114/wo.2013.38564. Epub 2013 Nov 14.

PMID:
24596534
[PubMed]
Free PMC Article
2.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

PMID:
22018631
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

PMID:
21892704
[PubMed - indexed for MEDLINE]
4.

Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG).

Tomova A, Bartsch R, Brodowicz T, Tzekova V, Timcheva C, Wiltschke C, Gerges DA, Pawlega J, Spanik S, Inbar M, Zielinski CC.

Breast Cancer Res Treat. 2010 Jan;119(1):169-76. doi: 10.1007/s10549-009-0553-4.

PMID:
19768533
[PubMed - indexed for MEDLINE]
5.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

PMID:
19692688
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

PMID:
19528136
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

PMID:
19474112
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

PMID:
18981464
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Optimization of the method of RNA isolation from paraffin blocks to assess gene expression in breast cancer.

Jarzab M, Rózanowski P, Kowalska M, Zebracka J, Rudnicka L, Stobiecka E, Jarzab B, Stachura J, Pawlega J.

Pol J Pathol. 2008;59(2):85-91.

PMID:
18669173
[PubMed - indexed for MEDLINE]
10.

[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].

Zygulska AL, Pawlega J.

Przegl Lek. 2008;65(12):825-8. Polish.

PMID:
19441672
[PubMed - indexed for MEDLINE]
11.

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.

Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T.

J Clin Oncol. 2005 Mar 1;23(7):1401-8.

PMID:
15735116
[PubMed - indexed for MEDLINE]
12.

[Ovarian cancer--therapeutic options after the failure of the first line of treatment].

Jabłońska E, Chłosta M, Pawlega J.

Ginekol Pol. 2004 Jan;75(1):58-64. Review. Polish.

PMID:
15112475
[PubMed - indexed for MEDLINE]
13.

Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ.

Patla A, Rudnicka-Sosin L, Pawlega J, Stachura J.

Pol J Pathol. 2002;53(1):25-7.

PMID:
12014222
[PubMed - indexed for MEDLINE]
14.

[Single sigmoidoscopy for screening of colorectal cancer].

Pawlega J, Richter P, Kurek S, Szura M.

Pol Merkur Lekarski. 2000 Nov;9(53):772-4. Polish.

PMID:
11204327
[PubMed - indexed for MEDLINE]
15.

Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study.

Gatta G, Capocaccia R, Sant M, Bell CM, Coebergh JW, Damhuis RA, Faivre J, Martinez-Garcia C, Pawlega J, Ponz de Leon M, Pottier D, Raverdy N, Williams EM, Berrino F.

Gut. 2000 Oct;47(4):533-8.

PMID:
10986214
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Monitoring of bone metastases].

Pawlega J, Adamczyk A.

Pol Merkur Lekarski. 2000 Mar;8(45):151-4. Review. Polish.

PMID:
10870423
[PubMed - indexed for MEDLINE]
17.

[Current possibilities for the decrease of mortality risk in patients with head and neck cancers].

Pawlega J.

Otolaryngol Pol. 1998;52(2):199-202. Polish.

PMID:
9673121
[PubMed - indexed for MEDLINE]
18.

[Survival of patients with the most frequent malignant neoplasms in the population of Krakow in the years 1985-1989].

Pawlega J, Urbańska A.

Pol Merkur Lekarski. 1997 May;2(11):315-7. Polish.

PMID:
9377679
[PubMed - indexed for MEDLINE]
19.

Evaluation of certain risk factors for lung cancer in Cracow (Poland)--a case-control study.

Pawlega J, Rachtan J, Dyba T.

Acta Oncol. 1997;36(5):471-6.

PMID:
9292742
[PubMed - indexed for MEDLINE]
20.

Dietary factors and risk of prostate cancer in Poland. Results of case-control study.

Pawlega J, Rachtan J, Dyba T.

Neoplasma. 1996;43(1):61-3.

PMID:
8843963
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk